MedTrace Logo

The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)

NCT00856960 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-01-22

No results posted yet for this study

Summary

This study will evaluate the effect of Aliskiren and Losartan on renal blood flow using PAH clearance, PC MRA and ASL MRI methodologies.

Conditions

Interventions

DRUG

Aliskiren

Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period.

DRUG

Aliskiren

Single dose of one 150 mg tablet of Aliskiren in one of three study periods. There will be at least 10 days between each study period.

DRUG

Comparator: Losartan

Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period.

DRUG

Comparator: Placebo to Aliskiren

Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.

DRUG

Comparator: Placebo to Losartan

Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-03-31
Completion
2010-04-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00856960 on ClinicalTrials.gov